Obaldía MAP, Delgado REJ, Rocha MSM

Language: Spanish
References: 16
Page:
PDF size: 233.80 Kb.

ABSTRACT

Cutaneous leishmaniasis is a skin infection caused by a parasite, transmitted by the bite of a vector. Leishmania is endemic in many regions of the world, such as Central and South America and Africa. The type of Leishmania that is most frequently associated with cutaneous leishmaniasis is Leishmania brazilensis. The vectors responsible for inoculating leishmania in patients are of the genus Phlebotomus.The diagnosis of cutaneous leishmaniasis is made through clinical suspicion, due to the characteristic ulcer on exposed skin and is confirmed by histology, by direct observation of the parasite under the microscope. The first-line treatment for this pathology is pentavalent antimony in monotherapy or in combination, in which better response rates have been observed.

REFERENCES

1. Abadías-Granado I, Diago A, Cerro PA, Palma-Ruiz AM, Gilaberte Y. Cutaneous and Mucocutaneous Leishmaniasis. Actas Dermo-Sifiliográficas. 2021;112:601-18.

2. Aronson NE, Joya CA. Cutaneous Leishmaniasis: Updates in Diagnosis and Management. Infectious Disease Clinics of North America. W.B. Saunders. 2019;33:101-17.

3. Reimão JQ, Coser EM, Lee MR, Coelho AC. Laboratory diagnosis of cutaneous and visceral leishmaniasis: Current and future methods. Microorganisms. MDPI AG. 2020;8:1-30.

4. Pinart M, Rueda JR, Romero GAS, Pinzón-Flórez CE, Osorio-Arango K, Silveira Maia-Elkhoury AN, et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2020.

5. Barkati S, Ndao M, Libman M. Cutaneous leishmaniasis in the 21st century: From the laboratory to the bedside. Current Opinion in Infectious Diseases. Lippincott Williams and Wilkins. 2019;32:419-25.

6. Jaramillo Antillón O, Espinoza Aguirre A, Calvo Fonseca N, Mata Somarribas C, Wasserman H. La leishmaniosis cutánea en Costa Rica: prevención, diagnóstico y tratamiento. Acta Med Costarric. 29 de noviembre, 2018;60(3):103-14.

7. Bahrami F, Harandi AM, Rafati S. Biomarkers of cutaneous leishmaniasis. Frontiers in Cellular and Infection Microbiology. Frontiers Media S.A.; 2018.

8. Alidosti M, Heidari Z, Shahnazi H, Zamani-Alavijeh F. Behaviors and Perceptions Related to Cutaneous Leishmaniasis in Endemic Areas of the World: A Review. Acta Tropica. Elsevier B.V. 2021;223.

9. Burza S, Croft SL, Boelaert M. Leishmaniasis. The Lancet. Lancet Publishing Group; 2018;392:951-70.

10. Gurel MS, Tekin B, Uzun S. Cutaneous leishmaniasis: A great imitator. Clin Dermatol. 2020, Mar 1;38(2):140-51.

11. Sasidharan S, Prakash Saudagar &. Leishmaniasis: where are we and where are we heading? DOI: https://doi.org/10.1007/s00436-021-07139-2

12. Mann S, Frasca K, Scherrer S, Henao-Martínez AF, Newman S, RamananP, et al. A Review of Leishmaniasis: Current Knowledge and Future Directions. DOI: https://doi.org/10.1007/s40475-021-00232-7

13. Pradhan S, Schwartz RA, Patil A, Grabbe S, Goldust M. Treatment options for leishmaniasis. Clinical and Experimental Dermatology. John Wiley and Sons Inc. 2022;47:516-21

14. Berbert TRN, Mello TFP de, Wolf Nassif P, Mota CA, Silveira AV, Duarte GC, et al. Pentavalent antimonials combined with other therapeutic alternatives for the treatment of cutaneous and mucocutaneous leishmaniasis: A systematic review. Dermatology Research and Practice. Hindawi Limited; 2018;2018.

15. De Souza ML, dos Santos WM, de Sousa ALMD, Ferraz LR de M, da Costa LAG, Silva EO, et al. Cutaneous leishmaniasis: new oral therapeutic approaches under development. Int J Dermatol. 2022, Jan 1;61(1):89-98.

16. Husein-ElAhmed H, Gieler U, Steinhoff M. Evidence supporting the enhanced efficacy of pentavalent antimonials with adjuvant therapy for cutaneous leishmaniasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2216-2228. doi: 10.1111/jdv.16333. Epub 2020 Jul 3. PMID: 32118322.